Rockwell Medical (RMTI)
(Delayed Data from NSDQ)
$3.49 USD
+0.05 (1.45%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $3.48 -0.01 (-0.29%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Rockwell Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 84 | 73 | 62 | 62 | 61 |
Cost Of Goods | 75 | 69 | 64 | 59 | 58 |
Gross Profit | 9 | 4 | -2 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 21 | 28 | 31 | 37 |
Income After Depreciation & Amortization | -7 | -17 | -30 | -28 | -35 |
Non-Operating Income | 1 | 0 | 0 | -1 | 0 |
Interest Expense | 2 | 2 | 2 | 2 | 0 |
Pretax Income | -8 | -19 | -33 | -31 | -34 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -19 | -33 | -31 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -19 | -33 | -31 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -2 | -14 | -27 | -26 | -32 |
Depreciation & Amortization (Cash Flow) | 5 | 3 | 3 | 3 | 3 |
Income After Depreciation & Amortization | -7 | -17 | -30 | -28 | -35 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 23.32 | 9.87 | NA | 6.87 | 5.54 |
Diluted EPS Before Non-Recurring Items | -0.17 | -1.89 | NA | -4.51 | -6.16 |
Diluted Net EPS (GAAP) | -0.37 | -1.89 | -3.85 | -4.51 | -6.16 |
Fiscal Year end for Rockwell Medical, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 25.83 | 22.68 | 22.09 | 23.77 |
Cost Of Goods | NA | 21.28 | 19.61 | 19.22 | 21.57 |
Gross Profit | NA | 4.55 | 3.06 | 2.87 | 2.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.04 | 4.39 | 3.42 | 3.94 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.51 | -1.33 | -0.55 | -1.74 |
Non-Operating Income | NA | 0.06 | 0.02 | 0.14 | 0.28 |
Interest Expense | NA | 0.23 | 0.43 | 1.11 | 0.41 |
Pretax Income | NA | 0.34 | -1.73 | -1.51 | -1.87 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 0.34 | -1.73 | -1.51 | -1.87 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 0.34 | -1.73 | -1.51 | -1.87 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 30.45 | 29.33 | 28.65 | 27.52 |
Diluted EPS Before Non-Recurring Items | NA | 0.01 | -0.02 | 0.02 | -0.07 |
Diluted Net EPS (GAAP) | NA | 0.01 | -0.06 | -0.02 | -0.07 |